Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology

被引：0

作者：

Hirose, Takeshi ^{[1
]}

Ito, Mamoru ^{[2
]}

Tsuchihashi, Kenji ^{[2
]}

Ozaki, Yukinori ^{[3
]}

Nishio, Hiroshi ^{[4
]}

Ichihara, Eiki ^{[5
]}

Miura, Yuji ^{[6
]}

Yano, Shingo ^{[7
]}

Maruyama, Dai ^{[8
]}

Yoshinami, Tetsuhiro ^{[9
]}

Susumu, Nobuyuki ^{[10
]}

Takekuma, Munetaka ^{[11
]}

Motohashi, Takashi ^{[12
]}

Baba, Eishi ^{[13
]}

Ochi, Nobuaki ^{[14
]}

Kubo, Toshio ^{[15
]}

Uchino, Keita ^{[16
]}

Kimura, Takahiro ^{[17
]}

Kamiyama, Yutaro ^{[18
]}

Nakao, Shinji ^{[19
]}

Tamura, Shinobu ^{[20
]}

Nishimoto, Hitomi ^{[21
]}

Kato, Yasuhisa ^{[22
]}

Sato, Atsushi ^{[23
]}

Takano, Toshimi ^{[3
]}

Endo, Makoto ^{[1
]}

机构：

[1] Kyushu Univ, Dept Orthopaed Surg, Fukuoka, Japan

[2] Kyushu Univ, Dept Hematol Oncol & Cardiovasc Med, Fukuoka, Japan

[3] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Breast Med Oncol, Tokyo, Japan

[4] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan

[5] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan

[6] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan

[7] Jikei Univ, Sch Med, Dept Internal Med, Div Clin Oncol Hematol, Tokyo, Japan

[8] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan

[9] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, Osaka, Japan

[10] Int Univ Hlth & Welf, Narita Hosp, Dept Obstet & Gynecol, Chiba, Japan

[11] Shizuoka Canc Ctr, Dept Gynecol, Shizuoka, Japan

[12] Tokyo Womens Med Univ Hosp, Dept Obstet & Gynecol, Tokyo, Japan

[13] Kyushu Univ, Grad Sch Med Sci, Dept Oncol & Social Med, Fukuoka, Japan

[14] Kawasaki Med Sch, Dept Gen Internal Med 4, Okayama, Japan

[15] Okayama Univ Hosp, Dept Allergy & Resp Med, Okayama, Japan

[16] NTT Med Ctr Tokyo, Dept Med Oncol, Tokyo, Japan

[17] Jikei Univ, Sch Med, Dept Urol, Tokyo, Japan

[18] Jikei Univ, Sch Med, Dept Clin Oncol & Hematol, Tokyo, Japan

[19] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Med, Dept Hematol, Kanazawa, Ishikawa, Japan

[20] Wakayama Med Univ, Dept Hematol Oncol, Wakayama, Japan

[21] Okayama Univ Hosp, Dept Nursing, Okayama, Japan

[22] Shonan Univ Med Sci, Fac Pharmaceut Sci, Dept Drug Informat, Kanagawa, Japan

[23] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Hirosaki, Aomori, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2024年

关键词：

Granulocyte colony-stimulating factor; Non-round cell sarcoma; Soft tissue sarcoma; Chemotherapy; Adverse effects; ADJUVANT CHEMOTHERAPY; DOXORUBICIN; IFOSFAMIDE; METAANALYSIS; TRIALS;

D O I：

10.1007/s10147-024-02569-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundGranulocyte colony-stimulating factor (G-CSF) is an essential supportive agent for chemotherapy-induced severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for non-round cell soft tissue sarcoma (NRC-STS)?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve NRC-STS treatment outcomes?" for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.MethodsA literature search was performed on the primary prophylactic use of G-CSF for NRC-STSs. Two reviewers assessed the extracted papers and analyzed overall survival, incidence of febrile neutropenia, infection-related mortality, quality of life, and pain.ResultsEighty-one and 154 articles were extracted from the literature search for CQs #1 and #2, respectively. After the first and second screening, one and two articles were included in the final evaluation, respectively. Only some studies have addressed these two clinical questions through a literature review.ConclusionThe clinical questions were converted to future research questions because of insufficient available data. The statements were proposed: "The benefit of primary G-CSF prophylaxis is not clear in NRC-STS" and "The benefit of intensified chemotherapy with primary G-CSF prophylaxis is not clear in NRC-STSs." G-CSF is often administered as primary prophylaxis when chemotherapy with severe myelosuppression is administered. However, its effectiveness and safety are yet to be scientifically proven.

引用

页码：1067 / 1073

页数：7